Back to Resource Hub Case Study

Endpoint Quality Solutions Support Rare Pediatric Disease Trial

A pharmaceutical sponsor conducting an important trial investigating a novel treatment for a pediatric rare disease needed to ensure the accuracy and reliability of its endpoint data.

Recognizing that their current vendor lacked the expertise, the sponsor engaged Signant to provide endpoint reliability solutions and services.

As global leaders in CNS, rare disease, and pediatric trials, Signant was prepared with proven solutions, scientific expertise, and experience rescuing studies to take the lead.

By redesigning the sponsor’s rater training program and applying our COA data analytics solution, we ensured that data derived from complex assessments were accurate and ready for regulatory review, ultimately leading to FDA approval of the first novel treatment for the rare pediatric disease.

Explore the case study for details, and contact our team if you need to get your trial back on track.

Similar posts

Looking for more insights? Explore related resources.

BLOG POST

5 Tips for Success in Rare Disease Studies

VISIT THE BLOG
ARTICLE

Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases

READ THE ARTICLE
BROCHURE

eCOA and Endpoint
Quality Solutions
for Orphan
Disease Research

SEE THE BROCHURE

Get notified on new marketing insights

Here mention the benefits of subscribing